The present invention related to a pharmaceutical composition with anti-IL-19 antibody for suppressing bone loss, which comprises: a first antibody in an effective amount, wherein the first antibody is an anti-IL-19 antibody or the antigen binding fragment thereof, and a pharmaceutical carrier. The pharmaceutical composition for the present invention further comprises a second antibody, wherein the second antibody is an anti-IL-20 antibody, anti-RANKL antibody, anti-IL-20 antigen binding fragment, or anti-RANKL antigen binding fragment. In addition, the first antibody and the second antibody of the present invention are a kind of engineered antibody such as a monoclonal antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a domain antibody.本發明係關於一種以抗IL-19抗體抑制骨質流失之醫藥組合物,該醫藥組合物係包含:有效劑量之一第一抗體,其中該第一抗體係為抗IL-19抗體或其抗原結合片段;以及一醫藥上可接受之載體。而本發明之醫藥組成物更包含一第二抗體,其中該第二抗體係為抗IL-20抗體、抗RANKL抗體、抗IL-20抗體之抗原結合片段、或抗RANKL抗體之抗原結合片段。此外,本發明之第一抗體及第二抗體係為一種基因工程抗體,如單株抗體、人源化抗體、嵌合抗體、單鏈抗體、或功能區塊抗體。
